Member Bio - Craig A. Wheeler

Craig A. Wheeler joined Momenta Pharmaceuticals, Inc. as Chief Executive Officer
in September 2006. He also serves as a member of the company’s board of directors.
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed
characterization and engineering of complex drugs. Under Wheeler’s leadership,
Momenta and its collaboration partner Sandoz received FDA approval for the first
ever generic Lovenox, and more recently generic Copaxone. Prior to Momenta,
Wheeler worked at Chiron Corporation as President, Chiron BioPharmaceuticals,
which had products treating cancer, cystic fibrosis, and multiple sclerosis. Wheeler
was also a senior member of The Boston Consulting Group’s health care practice,
worked for Merck’s MSDRL research unit as a senior engineer, and at Hybritech as a
financial analyst. He is Chairman of the Board of Directors of GPhA and in 2011 was
an E&Y Entrepreneur of the Year Regional Award winner. Previously, he was Chairman
of the Board of Avanir Pharmaceuticals. He holds a B.S. and an M.S. degree
in chemical engineering from Cornell University, and an M.B.A. from the Wharton
School of the University of Pennsylvania.

675 West Kendall Street
Cambridge, MA 02142
617 395-5158
Craig_wheeler@comcast.net